Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06381284 · ClinicalTrials.gov registry record
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
A clinical trial of Myasthenia Gravis and Neuromuscular Diseases, sponsored by ZS Associates.
- Completed
- Registry status
- 215
- Enrollment target
- 1
- Study location
NCT06381284: Completed study of Myasthenia Gravis and Neuromuscular Diseases, sponsored by ZS Associates.
NCT06381284 is a study of Myasthenia Gravis and Neuromuscular Diseases that has completed, run by ZS Associates. The registered enrollment target is 215 participants, above the 184-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (17% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06381284, a study of Myasthenia Gravis and Neuromuscular Diseases, has completed, sponsored by ZS Associates.
- COMPLETED
- Registry status
- 215 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The main study objective is to evaluate the feasibility of a social media recruitment campaign tied to a participant reported symptom survey and self-administered physical assessment tool to influence undiagnosed participants to seek care for suspected Myasthenia Gravis (MG).
Primary Outcome
Measure the engagement and feasibility metrics of the social media campaign
Conditions Studied
Interventions
- BEHAVIORAL Social media recruitment
- BEHAVIORAL Self-Assessment
- BEHAVIORAL Follow-up
Study Locations (1)
Illinois
- ZS Associates - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2025-03-03 |
What the finished NCT06381284 record still lists
NCT06381284 is an observational study that tracks outcomes without assigning an intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, above the 184-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (17% higher).
The record links to 3 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 3 interventions - of which Social media recruitment is the first listed.
NCT06381284 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06381284 about?
NCT06381284 is a clinical study titled "Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment". This is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The main study objective is to evaluate the feasibility of a social media recruitment campaign tied to a participant reporte...
What is the current status of trial NCT06381284?
This trial is currently completed. The enrollment target is 215 participants. The study started on 2024-03-28. Estimated completion is 2025-03-03.
What conditions does trial NCT06381284 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Neuromuscular Diseases, Neuromuscular Manifestations.
What interventions are being tested in trial NCT06381284?
The interventions under investigation include: Social media recruitment (BEHAVIORAL), Self-Assessment (BEHAVIORAL), Follow-up (BEHAVIORAL).
Who is sponsoring clinical trial NCT06381284?
This trial is sponsored by ZS Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06381284 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06381284's enrollment target sits among peer trials
215 9th of 32 higher than 24 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RECRUITING
-
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI